TY - JOUR
T1 - Treatment of the primary hyperoxalurias
T2 - A new chapter
AU - Milliner, D.
N1 - Funding Information:
Support of the International Registry for Primary Hyperoxaluria and the work of the Mayo Clinic Hyperoxaluria Center is provided by the Oxalosis and Hyperoxaluria Foundation and a grant from the National Institutes of Health, DK73354.
PY - 2006/10/9
Y1 - 2006/10/9
N2 - Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.
AB - Despite advances in the enzymology, molecular genetics, and clinical knowledge of the primary hyperoxalurias, few treatments are available. Oxalobacter formigenes is a promising new therapy with potential to induce secretion of oxalate into the intestinal lumen, where it can be degraded by the bacteria.
UR - http://www.scopus.com/inward/record.url?scp=33748923652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748923652&partnerID=8YFLogxK
U2 - 10.1038/sj.ki.5001821
DO - 10.1038/sj.ki.5001821
M3 - Comment/debate
C2 - 16988727
AN - SCOPUS:33748923652
VL - 70
SP - 1198
EP - 1200
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 7
ER -